Cancer name Head and Neck Cancer
Cancer Type HNSC
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment Cetuximab
Drugstatus Approved
Drugbank ID DB00002
Checkpoints NA
Signature Type Protein
Signature CD86
Official Symbol CD86
Mode of action PROT_R_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description Furthermore, we examined whether the addition of urelumab could enhance cetuximab-mediated DC maturation in the presence of NK cells. Compared to cetuximab alone, the addition of urelumab significantly enhanced HLA-DR and CD86 expression.
PMID 27496866
Title CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer